Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Veterinary Oncology Market, by Animal Type
1.4.2 Europe Veterinary Oncology Market, by Therapy
1.4.3 Europe Veterinary Oncology Market, by Cancer Type
1.4.4 Europe Veterinary Oncology Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Mergers & Acquisitions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2015-2019)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, Sep – 2019, Nov) Leading Players
Chapter 4. Europe Veterinary Oncology Market by Animal Type
4.1 Europe Canine Market by Country
4.2 Europe Feline Market by Country
Chapter 5. Europe Veterinary Oncology Market by Therapy
5.1 Europe Chemotherapy Market by Country
5.2 Europe Radiology Market by Country
5.3 Europe Surgery Market by Country
5.4 Europe Immunotherapy Market by Country
5.5 Europe Other Therapy Market by Country
Chapter 6. Europe Veterinary Oncology Market by Cancer Type
6.1 Europe Lymphoma Market by Country
6.2 Europe Mast Cell Cancer Market by Country
6.3 Europe Mammary & Squamous Cell Cancer Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe Veterinary Oncology Market by Country
7.1 Germany Veterinary Oncology Market
7.1.1 Germany Veterinary Oncology Market by Animal Type
7.1.2 Germany Veterinary Oncology Market by Therapy
7.1.3 Germany Veterinary Oncology Market by Cancer Type
7.2 UK Veterinary Oncology Market
7.2.1 UK Veterinary Oncology Market by Animal Type
7.2.2 UK Veterinary Oncology Market by Therapy
7.2.3 UK Veterinary Oncology Market by Cancer Type
7.3 France Veterinary Oncology Market
7.3.1 France Veterinary Oncology Market by Animal Type
7.3.2 France Veterinary Oncology Market by Therapy
7.3.3 France Veterinary Oncology Market by Cancer Type
7.4 Russia Veterinary Oncology Market
7.4.1 Russia Veterinary Oncology Market by Animal Type
7.4.2 Russia Veterinary Oncology Market by Therapy
7.4.3 Russia Veterinary Oncology Market by Cancer Type
7.5 Spain Veterinary Oncology Market
7.5.1 Spain Veterinary Oncology Market by Animal Type
7.5.2 Spain Veterinary Oncology Market by Therapy
7.5.3 Spain Veterinary Oncology Market by Cancer Type
7.6 Italy Veterinary Oncology Market
7.6.1 Italy Veterinary Oncology Market by Animal Type
7.6.2 Italy Veterinary Oncology Market by Therapy
7.6.3 Italy Veterinary Oncology Market by Cancer Type
7.7 Rest of Europe Veterinary Oncology Market
7.7.1 Rest of Europe Veterinary Oncology Market by Animal Type
7.7.2 Rest of Europe Veterinary Oncology Market by Therapy
7.7.3 Rest of Europe Veterinary Oncology Market by Cancer Type
Chapter 8. Company Profiles
8.1 Boehringer Ingelheim International GmbH
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Karyopharm Therapeutics, Inc.
8.2.1 Company overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Regeneus Ltd.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expense
8.4 Elanco Animal Health, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.5 Zoetis, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Varian Medical Systems, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.6.5.2 Partnerships, Collaborations, and Agreements:
8.6.5.3 Product Launches and Product Expansions:
8.7 PetCure Oncology, LLC (Accelitech, LLC)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Partnerships, Collaborations, and Agreements:
8.8 AB Science SA
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Research & Development Expense
8.9 Rhizen Pharmaceuticals S.A.
8.9.1 Company Overview
8.1 Nippon Zenyaku Kogyo Co., Ltd.
8.10.1 Company Overview
Unique Offerings 